Definition
mTOR: A master regulator protein kinase hub which controls a variety of anabolic or catabolic cellular processes, such as protein synthesis, ribosomal biosynthesis, and autophagy, among others.
Basic Characteristics
Mechanistic (or mammalian) target of rapamycin (mTOR) is a highly conserved Ser/Thr protein kinase that governs versatile cellular signaling networks to regulate a wide range of anabolic and catabolic processes. It plays central roles in maintaining normal cellular functions and, when dysregulated, in diverse diseases. mTOR forms two quite distinct types of multiprotein complexes (mTOR complexes 1 and 2). The complexes are activated by different signals and exert their physiological effects via the distinct downstream substrates which it phosphorylates (**e and Proud 2014).
Both mTORC1 and mTORC2 contain the core component mTOR, plus mLST8 (mammalian ortholog of lethal with sec thirtee...
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Benavides-Serrato A, Lee J, Holmes B, Landon KA, Bashir T, Jung ME, Lichtenstein A, Gera J (2017) Specific blockade of Rictor-mTOR association inhibits mTORC2 activity and is cytotoxic in glioblastoma. PLoS One 12:e0176599
Chen X, Liu M, Tian Y, Li J, Qi Y, Zhao D, Wu Z, Huang M, Wong CCL, Wang HW, Wang J, Yang H, Xu Y (2018) Cryo-EM structure of human mTOR complex 2. Cell Res 28:518–528
Frias MA, Thoreen CC, Jaffe JD, Schroder W, Sculley T, Carr SA, Sabatini DM (2006) mSin1 is necessary for Akt/PKB phosphorylation, and its isoforms define three distinct mTORC2s. Curr Biol 16:1865–1870
Jacinto E, Facchinetti V, Liu D, Soto N, Wei S, Jung SY, Huang Q, Qin J, Su B (2006) SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell 127:125–137
Kang SA, Pacold ME, Cervantes CL, Lim D, Lou HJ, Ottina K, Gray NS, Turk BE, Yaffe MB, Sabatini DM (2013) mTORC1 phosphorylation sites encode their sensitivity to starvation and rapamycin. Science 341:1236566
Kang SA, O’Neill DJ, Machl AW, Lumpkin CJ, Galda SN, Sengupta S, Mahoney SJ, Howell JJ, Molz L, Hahm S, Vlasuk GP, Saiah E (2019) Discovery of Small-Molecule Selective mTORC1 Inhibitors via Direct Inhibition of Glucose Transporters. Cell Chem Biol 26:1203–1213 e13
Kim J, Guan KL (2019) mTOR as a central hub of nutrient signalling and cell growth. Nat Cell Biol 21:63–71
Mahoney SJ, Narayan S, Molz L, Berstler LA, Kang SA, Vlasuk GP, Saiah E (2018) A small molecule inhibitor of Rheb selectively targets mTORC1 signaling. Nat Commun 9:548
Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chene P, De Pover A, Schoemaker K, Fabbro D, Gabriel D, Simonen M, Murphy L, Finan P, Sellers W, Garcia-Echeverria C (2008) Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 7:1851–1863
Rodrik-Outmezguine VS, Okaniwa M, Yao Z, Novotny CJ, Mcwhirter C, Banaji A, Won H, Wong W, Berger M, De Stanchina E, Barratt DG, Cosulich S, Klinowska T, Rosen N, Shokat KM (2016) Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor. Nature 534:272–276
Schalm SS, Blenis J (2002) Identification of a conserved motif required for mTOR signaling. Curr Biol 12:632–639
Schreiber KH, Arriola Apelo SI, Yu D, Brinkman JA, Velarde MC, Syed FA, Liao CY, Baar EL, Carbajal KA, Sherman DS, Ortiz D, Brunauer R, Yang SE, Tzannis ST, Kennedy BK, Lamming DW (2019) A novel rapamycin analog is highly selective for mTORC1 in vivo. Nat Commun 10:3194
Thoreen CC, Sabatini DM (2009) Rapamycin inhibits mTORC1, but not completely. Autophagy 5:725–726
**e J, Proud CG (2013) Crosstalk between mTOR complexes. Nat Cell Biol 15:1263–1265
**e J, Proud CG (2014) Signaling crosstalk between the mTOR complexes. Translation (Austin) 2:e28174
**e J, Wang X, Proud CG (2016) mTOR inhibitors in cancer therapy. F1000Res 5:F1000 Faculty Rev-2078
**e J, Wang X, Proud CG (2018) Who does TORC2 talk to? Biochem J 475:1721–1738
Xu T, Zhang J, Yang C, Pluta R, Wang G, Ye T, Ouyang L (2021) Identification and optimization of 3-bromo-N’-(4-hydroxybenzylidene)-4-methylbenzohydrazide derivatives as mTOR inhibitors that induce autophagic cell death and apoptosis in triple-negative breast cancer. Eur J Med Chem 219:113424
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer Nature Switzerland AG
About this entry
Cite this entry
**e, J., Proud, C.G. (2021). mTOR Signaling Pathways. In: Offermanns, S., Rosenthal, W. (eds) Encyclopedia of Molecular Pharmacology. Springer, Cham. https://doi.org/10.1007/978-3-030-57401-7_10068
Download citation
DOI: https://doi.org/10.1007/978-3-030-57401-7_10068
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-57400-0
Online ISBN: 978-3-030-57401-7
eBook Packages: Biomedical and Life SciencesReference Module Biomedical and Life Sciences